<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7706726</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2822</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Clin Ther</journal-id>
<journal-title-group>
<journal-title>Clinical therapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0149-2918</issn>
<issn pub-type="epub">1879-114X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26973296</article-id>
<article-id pub-id-type="pmc">5206974</article-id>
<article-id pub-id-type="doi">10.1016/j.clinthera.2016.02.008</article-id>
<article-id pub-id-type="manuscript">NIHMS832053</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neonatal Gastrointestinal and Respiratory Microbiome in Cystic Fibrosis: Potential Interactions and Implications for Systemic Health</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Madan</surname>
<given-names>Juliette C.</given-names>
</name>
<degrees>MD, MS</degrees>
<aff id="A1">Division of Neonatology, Department of Pediatrics, Children's Hospital at Dartmouth, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="FN1">Address correspondence to: Juliette C. Madan, MD, MS, Division of Neonatology, Department of Pediatrics, Children's Hospital at Dartmouth, Geisel School of Medicine at Dartmouth, 1 Rope Ferry Road, Hanover, NH 03755. <email>juliette.c.madan@hitchcock.org</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p><bold>Conflicts of Interest</bold>: The author has indicated she has no conflicts of interest regarding the content of this article.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>11</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>03</day>
<month>1</month>
<year>2017</year>
</pub-date>
<volume>38</volume>
<issue>4</issue>
<fpage>740</fpage>
<lpage>746</lpage>
<!--elocation-id from pubmed: 10.1016/j.clinthera.2016.02.008-->
<abstract>
<sec id="S1">
<title>Purpose</title>
<p id="P1">The gastrointestinal microbiome plays a critical role in nutrition and metabolic and immune functions in infants and young children and has implications for lifelong health. Cystic fibrosis (CF) transmembrane conductance regulator (<italic>CFTR</italic>) mutations in CF result in viscous mucous production, frequent exposure to antibiotics, and atypical colonization patterns, resulting in an evolving dysbiosis of the gastrointestinal and respiratory microsystems; dysbiosis in CF results in systemic inflammation, chronic infection, and dysregulation of immune function. Dysbiosis in both the respiratory system and gut contributes to undernutrition, growth failure, and long-term respiratory and systemic morbidity in infants and children with CF. Understanding the role that the gut and respiratory microbiome plays in health or disease progression in CF will afford opportunities to better identify interventions to affect clinical changes.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P2">Summary was done of the pertinent literature in CF and the study of the microbiome and probiotics.</p>
</sec>
<sec id="S3">
<title>Findings</title>
<p id="P3">New studies have identified bacteria in the respiratory tract in CF that are typically members of the intestinal microbiota, and enteral exposures to breast milk and probiotics are associated with prolonged periods of respiratory stability in CF.</p>
</sec>
<sec id="S4">
<title>Implications</title>
<p id="P4">Understanding the complex interactions between the <italic>CFTR</italic> mutations, microbial colonization, and mucosal and systemic immunity is of major importance to inform new treatment strategies (such as restoring a healthier microbiome with probiotics or dietary interventions) to improve nutritional status and immune competence and to decrease morbidity and mortality in CF.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Infant</kwd>
<kwd>intestinal microbiome</kwd>
<kwd>respiratory microbiome</kwd>
<kwd>probiotics</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>